Addiction Treatment Services

Addiction is a chronic disease, which causes individuals to seek “reward” from substance-use or other activities whether or not they may cause harm. Addiction treatment has been in the spotlight as payers, policymakers, and health systems struggle to address the opioid crisis and increasing substance-related mortality rates. As a result, the addiction treatment market is shifting—there is expanded coverage for residential treatment, a push towards greater integration and care coordination, and new competitors entering the market—creating new challenges and opportunities for organizations working in addiction treatment.

Latest Resources

• Oregon’s System Of Care 2026-2029 Strategic Plan
• WestCare Opens 56-Bed Residential Addiction Treatment Facility In West Virginia
• Prevalence Of Global Mental Disorders Nearly Doubled Since 1990, Now Affecting 1.2 Billion People Worldwide
• Monthly Injectable Buprenorphine Associated With 56% Fewer Inpatient Visits For People With Opioid Use Disorder
• Ohio Medicaid Announces New Prior Authorization Standards To Strengthen Oversight Of Behavioral Health Services
• 10 New States Selected To Join CCBHC Medicaid Demonstration Program
• Forward Motion On CCBHCs
• Transcranial Magnetic Stimulation Reduced Cigarette Use More Than Sham Treatment In Small Study
• U.S. Drug Overdose Deaths Decline For Third Year, Down 14% Between 2024 & 2025
• Treatment In The Fentanyl Era 
• Individuals With ADHD & SUD Nearly Twice As Likely To Stop ADHD Medication Within One Year
• 17% Of Formerly Homeless Veterans With Opioid Use Disorder Received MOUD Within One Year Of Supportive Housing Placement
• SAMHSA Updates MOUD Guidance, Says Medication-Only Opioid Treatment Models Are Insufficient
• For Integration Success, Digital Anyone?
• SAMHSA Dear Colleague Letter: Updated Guidance On Medication Assisted Treatment/Medication For Opioid Use Disorder

See All

GLP-1 Medications Linked To 15%–20% Lower Risk Of Substance Use Disorders In Veterans With Type 2 Diabetes

Researchers from the Veterans Affairs St. Louis Health Care System found that veterans with type 2 diabetes who were prescribed glucagon-like peptide-1 receptor agonists (GLP-1s) had a lower risk of developing substance use disorders (SUDs) compared to those prescribed sodium-glucose cotransporter-2 (SGLT-2) inhibitors, according to a study published in The BMJ. The study was conducted to examine whether GLP-1 medications—originally developed to treat type 2 diabetes and increasingly used for weight management—are associated with differences… Read

• Breaking Down Silos: How One State Achieved 98% Faster Referral Response With Integrated Data & Coordination Tools
• DEA Reschedules FDA-Approved & State-Licensed Medical Marijuana Products; Hearing Set On Broader Marijuana Reclassification
• Community Healthlink In Massachusetts Prepares Program Transitions Ahead Of Closure
• CaredFor Launches Post-Discharge Measurement-Based Care Platform For Addiction Treatment Provider Organizations
• Finding ROI In MOUD

To sign-up for bi-weekly Mental Health alerts, you must be signed in to your account.